NCT07116928尚未招募4 期
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 1,244 人开始时间: 2025年11月30日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 1,244
- 试验地点
- 1
- 主要终点
- The average change in eGFR as measured by the total slope of eGFR from baseline to week 120
研究概览
简要总结
This study aims to investigate the impact of adding Ganagliflozin tablets to the current background therapy on preventing the progression of kidney disease in subjects with type 2 diabetes and chronic kidney disease. The efficacy and safety will be evaluated by comparing the effects of Ganagliflozin tablets and placebo tablets added to the current background treatment over 120 weeks
详细描述
A phase IV clinical study on the efficacy and safety of Ganagliflozin in treating patients with type 2 diabetes and chronic kidney disease (multicenter, randomized, double-blind, placebo parallel controlled). 1244 subjects all received a stable dose of ACEi or ARB for at least 4 weeks before enrollment.
Efficacy assessment: Compared with the placebo group, time to the first occurrence of kidney disease progression and the changes in eGFR slope, UACR, and score of KDQOL-36 were evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female individuals aged 18 years and above;
- •Meets the diagnostic criteria for T2DM;
- •Meets the diagnostic criteria for CKD, during the screening period（CKD-EPI Formula）: eGFR ≥ 30 to < 60 mL/min/1.73m^2, and UACR is ≥ 30 to < 5000 mg/g; Or eGFR ≥ 60 to < 90 mL/min/1.73m^2, and UACR is ≥ 300 to < 5000 mg/g ;
- •HbA1c ≥ 6.5% to ≤ 12%;
- •If there are no contraindications or special instructions, all subjects must take a stable dose of ACEi or ARB at least 4 weeks before randomization;
排除标准
- •Patients with type 1 diabetes or other special types of diabetes;
- •A medical history or clinical evidence indicating that the subjects have other primary kidney diseases and secondary kidney diseases other than type 2 diabetes (including but not limited to lupus nephritis, ANCA-related nephritis);
- •History of kidney transplantation;
- •Blood potassium level > 5.5 mmol/L during the screening period.
- •New York Heart Association (NYHA) classification of grade IV during the screening period;
- •Experienced ketoacidosis, myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack (TIA), hospitalization due to heart failure, or hospitalization due to urinary tract infection or acute kidney injury within 12 weeks before the screening period;
- •Receiving ACEi and ARB in combination;
- •Receiving mineralocorticoid receptor antagonists (MRA) or direct renin inhibitors (DRI) within 8 weeks before randomization;
- •Receiving drugs with immunosuppressive effects (such as cyclophosphamide, cyclosporine A, tacrolimus, etc.) or biological agents (rituximab, belimumab, etc.) during the 12 weeks before the screening period;
- •Receiving SGLT-2 inhibitors or GLP-1 receptor agonists within 8 weeks before the screening, or have previously used SGLT-2 inhibitor drugs and discontinued due to poor efficacy.
研究组 & 干预措施
ganagliflozin
Experimental
50 mg Once daily, 120 weeks
干预措施: ganagliflozin (Drug)
placebo
Placebo Comparator
50 mg Once daily, 120 weeks
干预措施: Placebo (Drug)
结局指标
主要结局
The average change in eGFR as measured by the total slope of eGFR from baseline to week 120
时间窗: Baseline to Week 120
次要结局
- Time to the first occurrence of kidney disease progression(from baseline to Week 120)
- The proportion of subjects with a total slope of eGFR greater than -3 mL/min/1.73 m²/year from baseline to week 120(from baseline to week 120)
- The average change in eGFR as measured by the total slope of eGFR from baseline to week 2 and week 8，from week 2 and week 8 to week 120(from baseline to week 2 and week 8，from week 2 and week 8 to week 120)
- The changes in urine albumin-to-creatinine ratio (UACR) at each visit compared to the baseline(from baseline to week 120)
- Changes in the scores of the Kidney Disease Quality of Life-36 Scale (KDQOL-36) compared to the baseline(from baseline to week 120)
- Changes in the scores of the European Five-Dimensional Health Scale (EQ-5D-5L) compared to the baseline(from baseline to week 120)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)Diabetes Mellitus, Type 1NCT02139943Janssen Research & Development, LLC352
已完成
4 期
A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and SitagliptinDiabetes Mellitus, Type 2NCT02025907Janssen Research & Development, LLC218
已完成
4 期
A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes MellitusAlbuminuriaDiabetes Mellitus, Type 2NCT01989754Janssen Research & Development, LLC5,813
已完成
3 期
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT01106651Janssen Research & Development, LLC716
已完成
3 期
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus GlimepirideDiabetes Mellitus, Type 2NCT00968812Janssen Research & Development, LLC1,452